Iluka Resources

Phase A — Understand the business

Company Overview

Iluka Resources is the world's largest producer of zircon and a major producer of high-grade titanium-dioxide feedstocks (rutile and synthetic rutile, "SR"), now pivoting to become the first fully-integrated rare-earths refiner outside China. The business runs in three reportable buckets: Mineral Sands (the legacy cash engine), Rare Earths (the Eneabba refinery under construction), and Idle/Closed assets.

What it actually sells, and to whom:

• Zircon — an opacifier and refractory mineral. End-uses in FY2025 split ~45% ceramics (tiles, sanitaryware), 29% refractory & foundry, 24% fused zirconia & chemicals, 2% other. China is the largest zircon market; European demand for tile/sanitaryware opacifiers held firmer than China through 2025.
• Titanium feedstocks (rutile, synthetic rutile, ilmenite, HyTi) — ~90% consumed by the TiO₂ pigment industry (paint, plastics, paper), the rest by titanium-metal customers. This is the segment that broke in 2025: pigment demand was cyclically depressed, compounded by Western pigment-plant closures and tariff distortions.
• Rare-earth oxides (from 2027) — separated light and heavy REOs: neodymium, praseodymium, dysprosium, terbium and others, capacity up to ~23,000 tpa REO at Eneabba.

Asset base:

• Jacinth-Ambrosia (South Australia) — the world's largest zircon mine; the crown jewel of the zircon franchise.
• Cataby (Western Australia) — a large ilmenite deposit with zircon/rutile by-product; production suspended Sept 2025 amid the pigment downturn (see Lens 5/10).
• Narngulu mineral separation plant (WA) — one of the largest MSPs globally; processes HMC from Jacinth-Ambrosia and Cataby.
• Synthetic rutile kilns (Capel, WA) — SR1 and SR2; SR2 suspended Sept 2025.
• Balranald (NSW) — new underground/deep mineral-sands development; mining of run-of-mine ore began Jan 2026, first HMC due 2026, finished goods at Narngulu in H1 2027.
• Eneabba (WA, ~280km north of Perth) — the integrated rare-earths refinery, >50% complete and within the A$1.7–1.8bn capital estimate, commissioning targeted mid-2027.
• Sierra Rutile (Sierra Leone) — historically a separate African rutile operation; Iluka has been demerging/divesting this (Sierra Rutile Holdings was demerged in 2022; residual disclosures remain).
• Wimmera (Victoria) — large long-life zircon + rare-earths resource flagged as a future Eneabba feedstock.

Contract structure — the structurally important part. Iluka has shifted toward fixed-or-floor priced minimum-revenue contracts: for 2026 it has contracted ~110kt SR, 10kt rutile, 12kt HyTi and 100kt ilmenite with Western pigment customers underpinning minimum contracted revenue of ~A$240m. The first Eneabba rare-earths offtake (announced early 2026) with a global automaker is a four-year take-or-pay for ~1,200t of magnet REO (Nd/Pr/Dy/Tb) from 2028, with a US$155m minimum revenue floor (~US$172m at industry-forecast pricing, an ~11% uplift). That floor is the bankability anchor for a non-recourse refinery (Lens 11).

is empty — no compiled customer concentration. From the contract structure, concentration risk sits at the pigment-customer level (Western producers) for titanium feedstocks and at the single-automaker level for the first REO offtake.

Supply Chain

Iluka is unusually vertically integrated for a miner — it mines, separates, and (from 2027) refines, which is the whole strategic point. Named chain, upstream → end customer:

Upstream inputs / suppliers:

• Ore bodies (self-supplied) — Jacinth-Ambrosia (zircon), Cataby (ilmenite, suspended), Balranald (rutile/zircon/SR/ilmenite + rare-earth concentrate from 2026/27), plus the Eneabba stockpile (a high-grade monazite-rich rare-earth concentrate stockpile already on site — Iluka's existing feedstock for refinery start-up).
• Third-party rare-earth concentrate — Eneabba is designed to process external feedstock too. Iluka signed a rare-earth concentrate supply agreement with Lindian Resources (Kangankunde, Malawi). This is the "merchant refiner" optionality.
• EPCM / construction — Fluor is the EPCM contractor on Eneabba. Construction inputs: concrete, piling, a high-voltage powerline, gas metering — all flagged delivered/ramping in the Sept 2025 quarterly.
• Government capital — Export Finance Australia (EFA) is effectively a financing "supplier": A$1.25bn first-tranche non-recourse loan, lifted to a A$1.65bn total facility (see Lens 11).

Iluka (the converter): mine → Narngulu MSP (separation) → Capel SR kilns (ilmenite → synthetic rutile) → Eneabba refinery (monazite/concentrate → separated REOs, from 2027).

Downstream / end customers:

• Zircon → ceramic-tile & sanitaryware makers (China, Europe, India), refractory/foundry, fused-zirconia/chemicals. Logistics: export via Port of Bunbury and SA ports.
• Titanium feedstocks → TiO₂ pigment producers (the named buyer class — Western pigment majors; competitors/peers Chemours, Tronox are also customers' competitors), titanium-metal customers.
• Rare-earth oxides (2028+) → magnet makers / automakers (the first offtake is a global automaker), defence and electrification supply chains seeking ex-China REOs.

Chokepoints / single-source dependencies:

1. Narngulu MSP is the single separation hub for WA/SA feed — a concentration point.
2. Eneabba refinery execution — one asset, one EPCM contractor, one government lender; the entire rare-earths thesis funnels through it.
3. China on the demand side for zircon and China on the supply side for rare-earth pricing — Iluka is short China-zircon-demand and long ex-China-REO-scarcity simultaneously.

Names present, chain mapped — lens satisfied. (supply-chain.md commercial-layer file is missing; this is web-derived.)

Competitive Advantages (moats)

Mineral sands — a cost/scale moat that is real but cyclical.

• Jacinth-Ambrosia is the world's largest zircon mine. Scale + grade gives Iluka genuine cost leadership in zircon, and a degree of price-setting influence in a concentrated zircon market (Iluka, Tronox, Chemours, Base/African producers). Iluka has historically published a "zircon reference price" — a signal of pricing power.
• That moat is eroding at the margin: new Australian and South African zircon supply has pushed prices from >US$2,000/t (2024) to ~US$1,400/t CIF China (FY25). Cost leadership protects margin in a downturn but does not stop the price falling.

Bargaining power is currently weak on the sell side (pigment customers hold the cards in a glut — Iluka withdrew SR sales guidance because customers wouldn't commit) but the fixed-or-floor contracts claw some of it back by guaranteeing minimum volumes/revenue.

Rare earths — a policy-and-scarcity moat under construction. This is the durable-moat story:

• Integration: Eneabba will be one of very few facilities anywhere outside China able to separate both light AND heavy REOs. Heavy-REO separation (Dy/Tb) is the genuinely scarce capability — China still dominates it and never lifted its April-2025 heavy-REO export licensing (Lens 8).
• First-mover + government backing: A$1.65bn of mostly non-recourse government capital is a moat competitors can't easily replicate; it is also a sovereign endorsement that helps win Western offtake.
• Switching costs / customer captivity: a take-or-pay automaker offtake with a revenue floor is a sticky, multi-year relationship — the opposite of the spot-pricing weakness in zircon.

Net moat verdict: the existing moat (zircon scale) is a depleting cyclical advantage; the prospective moat (ex-China integrated REO refining) is potentially far more durable but unproven and entirely execution-dependent. The bet is a moat transplant. (positioning.md/bottlenecks.md missing; web-derived.)

Segments

our figures is empty — no compiled segment rows. The following is web-sourced and should be treated as such.

Within Z/R/SR (FY2025): zircon ≈ 65% of Z/R/SR revenue. Zircon sand sales 157kt + zircon-in-concentrate 111kt; zircon premium/standard price US$1,643/t (FY24: US$1,882/t). Blended Z/R/SR unit revenue A$1,913/t, −12.9% YoY. Total Z/R/SR production 559kt (above 495kt guidance; FY24 496kt) — Iluka out-produced into a falling-price market, which is part of the inventory problem (Lens 10).

Geography (FY2025, qualitative): China = largest zircon market, cautious/destocking; Europe firmer (opacifiers); global ceramic-tile production still contracting, led by China. No geographic revenue split available — n/a for a precise by-region table.

---

Phase B — Measure performance

Earnings Result (FY2025, reported 18 Feb 2026)

The headline: a statutory net loss of A$288m vs. A$231m profit in FY2024 — but the loss is manufactured by impairments; the cash business still made money.

Revenue & profit:

• Mineral Sands revenue A$976m (−13.5%).
• Underlying Group EBITDA A$329m (FY24 A$499m); Underlying Mineral Sands EBITDA A$300m (FY24 A$477m).
• Statutory net loss A$288m, after A$566m pre-tax exceptional items.

The A$566m exceptional breakdown:

• ~A$350m non-cash impairment of the Mineral Sands business — specifically Cataby mine, SR kilns 1 & 2, and South-West WA study costs.
• ~A$215m net-realisable-value inventory write-down — predominantly Cataby ore + HMC work-in-progress.
• Accompanied by a 35% cut to Cataby's Ore Reserve (group reserves −~7%), shortening Cataby's restart mine-life to ~4 years.

Production & cost (the bright spot): Z/R/SR production 559kt vs 495kt guidance; unit cash cost US$1,054/t, below guidance — higher zircon volume diluted unit cost.

Balance-sheet flags (see Lens 10 for forensic detail): inventory balance ~A$1.1bn at 31 Dec 2025 after the NRV write-down — i.e. inventory still exceeds a full year of mineral-sands revenue. Net debt building fast: rare-earths-segment net debt A$584m + mineral-sands net debt A$473m at 31 Dec 2025 — combined ≈ A$1.06bn.

Guidance & outlook: management declined to give zircon volume/price guidance through much of 2025 (tariff uncertainty, customer reluctance) — a tone marker. FY2026 framed around lower cash outflow: 2026 cash requirements ~A$665m (down from 2025), 2026 cash costs of production ~A$420m (FY25 ~A$590m). Minimum contracted mineral-sands revenue ~A$240m for 2026.

Dividend: final 3cps fully franked; full-year 5cps (FY24 8cps) — a 37.5% cut, consistent with capital being redirected to Eneabba/Balranald.

Market reaction: brutal and repeated. Shares fell as much as −17% on the impairment/suspension news (worst session since March 2020), and −11–13% on other 2025/26 sessions. The market is trading the cycle and the capex cliff, not the rare-earths option — yet over the trailing 6 months ILU outperformed the All Ords by +19.25% as the REO narrative reasserted. High two-way volatility is the signature.

Earnings Calls (sentiment trend)

transcripts/ is empty — this is web-derived from the public call transcripts and presentations (HY25 20-Aug-2025, FY25 18-Feb-2026, Q4/full-year 29-Jan-2026, Macquarie Conf May-2025; all on iluka.com).

Tone arc across 2025–26:

• May 2025 (Macquarie Conf): O'Leary framing the period as "exciting" — rare-earths-forward, growth narrative.
• Aug 2025 (HY25): still constructive but the pigment downturn entering the language; liquidity buffer + FX collars emphasised (defensive framing creeping in).
• Sept 2025 (Cataby/SR2 suspension): the pivot point — management stops talking growth and starts talking production discipline, cost-out, capital preservation. SR sales guidance withdrawn.
• Jan/Feb 2026 (Q4 + FY25): the dominant phrases become "lower 2026 capital outflows," "improved cash generation," "milestones on track at Balranald and Eneabba," "minimum contracted revenue." The story is explicitly "bridge through the trough to the 2027 rare-earths inflection."

What they started saying: rare-earths offtake, take-or-pay floors, government funding, "ex-China." What they stopped saying: zircon volume/price guidance (deliberately withheld), aggressive mineral-sands growth. Net: management has re-based expectations downward on mineral sands and re-anchored the equity story entirely on Eneabba — a tone shift from growth to survive-and-transform.

Comps

Iluka is a genuine two-business hybrid — mineral-sands (TiO₂-feedstock/zircon) peers AND rare-earths peers. Both sets shown. Multiples are with date or n/a. None fabricated.

5-yr avg ROE for the peer set: n/a (would be fabrication to assert; multiple peers are loss-making, making a clean 5-yr ROE meaningless without the underlying series).

Read: the rare-earths peers (Lynas ~83x EV/EBITDA, MP ~US$10.8bn on US$348m revenue) trade on strategic-scarcity multiples that have nothing to do with current earnings — they are repriced as sovereign-supply-chain assets. The mineral-sands peers (Chemours ~12.6x, Kenmare ~2.5x, Tronox) trade on cyclical-industrial multiples. Iluka sits awkwardly between: priced today closer to a cyclical mineral-sands miner (~A$3.46bn for a business that did A$329m underlying EBITDA), with a free rare-earths option the market only part-credits. If Eneabba delivers, the re-rate vector is toward the Lynas/MP cohort; if it stumbles, the floor is the mineral-sands cohort. That asymmetry is the entire investment case.

Stock-Price Catalysts (last ~5 years, the pattern)

What actually moves ILU >5%, from the visible record:

• Zircon/TiO₂ price & demand prints — the dominant driver historically. The 2024→2025 zircon de-rate (US$2,000→US$1,400) drove the structural drawdown.
• Impairment / suspension shock (Sept 2025 / Feb 2026): −17% on the Cataby/SR2 suspension + A$565m charge — worst day since Mar-2020. Withdrawal of SR sales guidance kicked off the sell-off.
• Refinery-delay / cost headlines: "Iluka shares drop on refinery delay" — Eneabba schedule/cost is now a first-order catalyst, both ways.
• Rare-earths policy & offtake headlines (2026): China export-control news and the first Eneabba offtake announcement drove the +19.25%-vs-index 6-month outperformance. The stock is now "a clean ASX play on ex-China rare-earth supply" — sensitive to policy headlines, not just commodity tape.
• Government-funding milestones (EFA tranche draws, the A$400m top-up to A$1.65bn) — sovereign-capital news de-risks and moves the stock. Confirmation of access to the final A$400m tranche (satisfying the last financing condition for completion) is a recent de-risking marker.

Pattern verdict: historically a commodity-price/earnings stock (zircon + TiO₂). It is transitioning into a policy/strategic-narrative stock (rare earths). 2025–26 is the awkward overlap where bad mineral-sands prints and good rare-earths headlines fight — hence the violent two-way volatility (52-wk range ~A$3.41–9.48 ).

---

Phase C — Judge people & books

Management

CEO: Tom (Thomas) O'Leary — MD/CEO since September 2016 (~9.5-yr tenure). Background: 30+ years in executive management, business development and investment banking; previously MD of Wesfarmers Chemicals, Energy & Fertilisers.

(1) Track record. O'Leary has run Iluka through a full mineral-sands cycle. The defining capital-allocation act of his tenure is the strategic pivot into rare earths — securing the Eneabba refinery and ~A$1.65bn of government funding, arguably positioning Iluka for a structural re-rate. He also oversaw the 2022 demerger of Sierra Rutile (separating the African asset) and Deterra Royalties (the iron-ore royalty spin-out, 2020) — both shareholder-value-conscious moves. Counter-mark: the FY2025 A$566m impairment and the Cataby reserve cut happened on his watch — capital was sunk into SW-WA assets now impaired.

(2) Tenure & skin in the game — a flag. O'Leary directly owns ~0.35% (~A$11.3m). More pointed: he conducted a ~A$5.5m share sale plus trust transfers, with no recent insider buying from CEO or Chair — characterised by at least one analyst as "not skin in the game; a pattern of sales and inaction". our figures is absent — cannot independently verify the full insider series; treat as. For a 9.5-year CEO selling into a transformation he's asking shareholders to fund, the optics are poor (Lens 13 weighs this).

(3) Capital-allocation history. Mixed-to-good historically (Deterra/Sierra Rutile demergers crystallised value; disciplined dividends in the up-cycle). Now in heavy-reinvest mode: dividend cut 8→5cps, capital funnelled into Eneabba + Balranald. The bet is enormous relative to the A$3.46bn market capMarket capitalisationThe share price multiplied by the number of shares. What the market says the equity is worth. — A$1.65bn government facility + Iluka equity. ROE/ROIC has gone negative in FY2025 on the impairment; on a normalised basis the historical returns were respectable. n/a for a clean multi-year ROIC series.

(4) Red flags. The CEO share-sale-without-buying pattern (above). No related-party or governance scandal surfaced. The 2022 shareholder class action was dismissed in full (Lens 10) — a clean disclosure record under litigation test.

(5) Founder vs professional manager. O'Leary is a professional manager / financier-operator (ex-IB, ex-Wesfarmers), not a founder. For a capital-intensive, government-financed transformation requiring project-execution discipline and balance-sheet stewardship, a financier-operator is arguably the right archetype — but the lack of personal buying means his alignment is via comp, not conviction.

Forensic Red Flags

Forensic-analyst lens. Web-only — no filings on the shelf to tie to. Figures labeled.

Income statement. The A$288m statutory loss is impairment-driven, not operational — the underlying business generated A$329m group EBITDA. Healthy that the charge is flagged as a discrete exceptional; unhealthy that it signals the SW-WA asset base (Cataby/SR kilns) was carried too high and is now reserve-cut 35%. Watch whether further impairments follow if zircon stays weak.

Balance sheet — the standout forensic flag: inventory. Inventory ~A$1.1bn at 31 Dec 2025 after a A$215m NRV write-down. That is inventory > a full year of mineral-sands revenue (A$976m) — an extreme build. Iluka out-produced guidance (559kt vs 495kt) into a falling-price, weak-demand market, accumulating finished/WIP stock. Bull read: a "zircon bank" — inventory monetisable when prices recover, deferred not destroyed value. Bear read: classic inventory outrunning sales, NRV risk if prices fall further, and cash trapped in working capital exactly when the company is funding two megaprojects. This is the single most important forensic line in the dossier — cash conversion is being strangled by inventory.

Net debt trajectory. Combined segment net debt ≈ A$1.06bn (RE A$584m + MS A$473m) at 31 Dec 2025, up from ~A$502m at June 2025. The EFA government loan is non-recourse (ring-fenced to the RE project) — a genuine structural protection: if Eneabba fails, the government loan does not sink the parent. But the mineral-sands segment net debt + the MOFA (A$800m facility, A$500m drawn, expires May 2029) is recourse, and that is the balance sheet that must survive the trough. Reported "net debt ~1.0x EBITDA" looks benign but rests on a trough EBITDA and excludes the working-capital drag.

Cash flow vs earnings. FCFFree cash flowCash left after paying to run and maintain the business. Unlike profit, it is hard to flatter with accounting choices. not cleanly sourced (n/a for an exact FY25 FCFFree cash flowCash left after paying to run and maintain the business. Unlike profit, it is hard to flatter with accounting choices. figure), but the directional read is clear: heavy capex (Eneabba/Balranald) + inventory build = negative free cash flow, funded by debt draws (MOFA + EFA). 2026 cash requirements ~A$665m against a business doing ~A$300–330m EBITDA means continued external funding reliance through 2026.

SBC / non-GAAP flattering. No evidence Iluka leans on SBC to flatter non-GAAP (it reports "underlying" cleanly stripping the A$566m exceptional). Not a flagged issue.

Regulatory findings (required sub-section):

• SEC (EDGAR LR + AAER): regulatory/regulatory-findings.md (fetched 2026-06-30) confirms Iluka has no CIK and is not an SEC filer — zero EDGAR enforcement possible. Not applicable to an ASX-only issuer.
• Australian / non-SEC enforcement (web): No new ACCC/ASIC enforcement actions, fines, or penalties surfaced for 2024–2026. The notable historical item is the shareholder class action Bonham v Iluka Resources Ltd [2022] FCA 71 — dismissed in full: the Federal Court found Iluka did not engage in misleading/deceptive conduct and did not breach continuous-disclosure obligations. A clean outcome — and a positive disclosure-integrity signal for a company whose forward story depends on guidance credibility.
• Item 3 / Legal Proceedings (10-K equivalent): n/a — no 10-KForm 10-KA company’s audited annual report to the US regulator. The most complete thing it publishes. (ASX filer); the annual-report "contingencies/legal" note is not on the local shelf, so n/a for a verbatim quote.
• Net: No material regulatory or legal findings — verified via SEC EDGAR EFTS (n/a — no CIK), web search (no 2024–26 hits), and the 2022 class-action dismissal, as of 2026-06-30.

---

Phase D — Project & stress-test

Forward Projection (FY2026–FY2028 EPS)

Build basis (all inputs → outputs; arithmetic shown). Shares outstanding ≈ ~430m. Caveat: market-cap-implied count (494m) conflicts with historical ~430m; I flag the conflict rather than pick silently. EPS below uses 430m; if 494m the per-share figures scale down ~13%.

FY2025 actuals: Mineral Sands revenue A$976m, Group underlying EBITDA A$329m, statutory net loss A$288m (impairment-driven), Z/R/SR 559kt, blended unit revenue A$1,913/t.

The honest answer: FY2026–27 EPS is dominated by (a) where zircon/TiO₂ prices land, and (b) Eneabba commissioning timing/cost — both genuinely uncertain. Rather than fabricate precision, three scenarios:

n/a for a precise sell-side consensus EPS line (the search surfaced price targets — avg ~A$7.66–8.07, range A$5.25–9.50 — but not a clean consensus EPS series; I will not fabricate one).

Brier forecast: skipped — per SKILL --watchlist rule, do not run our model create in the breadth loop. The base case is not yet a committed call. The natural binary to track later: "Eneabba refinery achieves first separated-REO production by 31 Dec 2027" (p ≈ 0.55 — management now guides mid-2027 commissioning at >50% complete and within budget, which nudges the base case up slightly, but megaproject base rates still argue for slippage risk).

Bull vs Bear

Bull case. Iluka is a cyclically-depressed mineral-sands cash cow stapled to the most strategically valuable rare-earths option on the ASX. The zircon franchise (Jacinth-Ambrosia, world's largest) is trough-earning, not broken — a price recovery flows straight to EBITDA given cost leadership, and the ~A$1.1bn inventory is a "zircon bank" that monetises on recovery. Meanwhile Eneabba makes Iluka one of very few ex-China integrated light+heavy REO refiners, ~A$1.65bn government-funded (mostly non-recourse — downside ring-fenced), with a first take-or-pay automaker offtake (US$155m floor) proving commercial bankability. China's heavy-REO export licensing (never lifted) is a structural tailwind that only grows. If Eneabba commissions in 2027 and re-rates ILU toward the Lynas/MP strategic-multiple cohort, the upside is multiples of today's A$3.46bn. Capital intensity peaks in 2026 then falls (cash needs A$665m, costs A$420m) — the cash-flow inflection is visible. Macquarie's top mineral-sands pick with a free rare-earths call option.

Bear case (2–3 permanent-impairment risks).

1. Eneabba is a megaproject that overruns or underperforms. It has already been re-costed (to A$1.7–1.8bn from earlier estimates) and needed a cost-overrun facility. A further blowout, a commissioning slip past 2027, or sub-spec heavy-REO recovery would impair the entire equity thesis — and the recourse mineral-sands balance sheet funds the gap.
2. Zircon/TiO₂ structural oversupply, not just a cycle. New Australian + South African zircon supply pushed prices US$2,000→US$1,400; if this is a structural glut (plus Chinese substandard rutile/leucoxene dumping in welding markets), the cash cow that funds the transformation is permanently lower-margin — and the A$1.1bn inventory faces further NRV write-downs.
3. Rare-earth pricing is China's to control. China suspended its Oct-2025 broad controls to Nov-2026 — Beijing can flood the market and crater NdPr/Dy prices to kneecap Western projects precisely when Eneabba ramps. The offtake floor (US$155m) protects a sliver of volume, not the whole P&L.

Pre-mortem (18 months out, thesis broke): Most likely failure mode — Eneabba commissioning slips to late-2028 with a A$200–400m overrun, while zircon stays ~US$1,300 and pigment demand never recovers. Iluka draws the full MOFA, cuts the dividend to zero, raises equity at a depressed price to plug the recourse balance sheet, and the "strategic re-rate" never arrives because China lets REO prices sag. The stock re-tests the A$3.41 low.

Are multiples too high? On trailing numbers Iluka screens as a loss-maker (no meaningful P/E); on EV/EBITDA it's ~mid-single-digits on trough EBITDA — not demanding for the mineral-sands business alone. The rare-earths option is only partly in the price. Multiples are not the risk — execution is.

Contrarian view (what the market refuses to see): The market is anchored on the zircon downturn and the capex cliff and treating Eneabba as a cost/risk. The contrarian read: Eneabba is a sovereign-strategic call option the West needs to work — and in a world re-pricing supply-chain security, a non-recourse-funded, government-sponsored, ex-China integrated heavy-REO refiner is worth far more as a strategic asset than a DCF on first-offtake economics suggests. The asymmetry (mineral-sands floor + strategic-REO upside) is being mis-weighted because 2026 is the ugly bridge year.

Devil's Advocate (short-seller)

Dismantling the bull case.

• The whole thesis is one unfinished asset. Strip Eneabba and you have a structurally-challenged cyclical mineral-sands miner losing money, cutting dividends, with A$1.1bn of inventory it couldn't sell and a CEO selling stock. The re-rate is 100% contingent on a megaproject that isn't built, isn't commissioned, and has already been re-costed upward once.
• Revenue concentration is brutal at the growth edge. The "proof" offtake is a single automaker, 1,200t, US$155m floor — that is rounding error against a A$1.65bn refinery. Where are the other offtakes? A refinery sized for ~23,000tpa REO with one small take-or-pay is a demand-risk asset dressed as a supply-security asset.
• The moat is weaker than bulls think. In zircon, new AU/SA supply is already eroding pricing power. In rare earths, Iluka is a late entrant behind Lynas (operating, separating, far bigger) and MP (mine-to-magnet, US-backed) — and China can reset REO prices at will, which structurally caps every ex-China refiner's economics regardless of "strategic value."
• Most dangerous competitor bulls underestimate: China's MOFCOM, not a company. Beijing's suspension of the Oct-2025 controls (to Nov-2026) is the tell — it can re-flood the market and make every Western refinery uneconomic on a spot basis, leaving Eneabba dependent on government price support to clear product.
• Capital-allocation flag: sinking ~A$1.65bn-facility-scale capital into a single refinery while the core business impairs A$566m and inventory balloons is betting the company on a transformation — and the CEO is a net seller of the stock. Incentive misalignment at the worst possible moment.
• Assumptions that must hold for A$7.00: (1) Eneabba commissions ~2027 near budget; (2) zircon doesn't fall further from US$1,400; (3) China doesn't crater REO prices; (4) the recourse balance sheet survives 2026 without dilutiveDilutionIssuing new shares, so each existing share owns a smaller slice of the same company. equity. If growth/prices disappoint 20–30%, underlying EBITDA drops toward A$200m, the MOFA gets stretched, and an equity raise at a depressed price permanently dilutes — the value-impairment scenario.
• Single permanent-impairment scenario, most plausible: Eneabba overrun + commissioning slip while REO prices sag — destroys the option that justifies the premium, and the recourse balance sheet absorbs the damage. Plausibility: moderate (megaproject base rates + China optionality make it the central bear risk, not a tail).

Management Questions (ordered by information value)

1. Eneabba is the entire re-rate thesis — give us the unvarnished commissioning date, the current all-in cost estimate vs the A$1.7–1.8bn budget, and the contingency remaining. What is the probability of first separated-REO production in calendar 2027?
2. Beyond the single automaker offtake, what is the contracted/committed order book for Eneabba's ~23,000tpa capacity — and what utilisation do you underwrite for FY2028–29?
3. If China keeps NdPr/Dy/Tb spot prices below your floor for years, what are Eneabba's economics on government price support alone — and is there any scenario where the refinery operates at a cash loss?
4. The recourse balance sheet (mineral-sands net debt + MOFA) funds the trough. At what zircon price and what Eneabba overrun would you need to raise equity — and have you modelled that line?
5. Inventory is ~A$1.1bn after a A$215m write-down — more than a year of mineral-sands revenue. What is the cash-realisation plan and timeline, and what zircon price assumption underpins the carrying value?
6. Is the zircon de-rate (US$2,000→US$1,400) a cycle or a structural oversupply? What gives you confidence in a recovery rather than a permanently lower price deck?
7. Cataby's reserve was cut 35% and the mine suspended. Under what zircon/ilmenite price do you restart — and if you don't, what's the residual value of the SW-WA assets you just impaired?
8. CEO and Chair have not bought stock and there have been insider sales. Why should shareholders fund a transformation that management isn't buying into personally?
9. The EFA loan is non-recourse to the RE project. Walk us through exactly what is ring-fenced vs what falls back on the parent if Eneabba underperforms.
10. Lindian and third-party feedstock — what tonnage is actually contracted into Eneabba, and what's your merchant-refining margin assumption vs self-supplied feed?
11. What is your through-the-cycle capital-allocation framework now: dividend policy, the bar for any further growth capex, and when (if ever) buybacks return?
12. Balranald starts producing in 2026 — what incremental EBITDA and rare-earth-concentrate volume does it add, and does its REE concentrate feed Eneabba?
13. How exposed is the rare-earths plan to US/Australia policy continuity (offtake support, the Critical Minerals Facility)? What changes if priorities shift?
14. What is the realistic mid-cycle group EBITDA once Eneabba is at nameplate and mineral sands normalises — the number that should anchor a fair multiple?
15. What is the single risk that keeps you up at night that the market is currently mispricing?

---